BioCryst Pharmaceuticals (NASDAQ:BCRX) Reaches New 12-Month High on Analyst Upgrade

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)’s stock price reached a new 52-week high during mid-day trading on Tuesday after Royal Bank Of Canada raised their price target on the stock from $13.00 to $14.00. Royal Bank Of Canada currently has an outperform rating on the stock. BioCryst Pharmaceuticals traded as high as $11.03 and last traded at $10.99, with a volume of 10180267 shares trading hands. The stock had previously closed at $10.17.

BCRX has been the subject of several other reports. Needham & Company LLC lowered their price target on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating for the company in a report on Wednesday, May 6th. Wedbush dropped their target price on BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Citizens Jmp lifted their target price on shares of BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the stock a “market outperform” rating in a research report on Thursday, May 7th. Wall Street Zen downgraded shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a report on Monday, June 1st. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, BioCryst Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $21.78.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Royal Bank of Canada grew its stake in BioCryst Pharmaceuticals by 2.4% during the first quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock worth $476,000 after purchasing an additional 1,458 shares during the period. Cetera Investment Advisers grew its position in shares of BioCryst Pharmaceuticals by 13.8% during the 4th quarter. Cetera Investment Advisers now owns 12,330 shares of the biotechnology company’s stock worth $96,000 after buying an additional 1,494 shares during the period. Captrust Financial Advisors increased its stake in shares of BioCryst Pharmaceuticals by 7.4% in the 2nd quarter. Captrust Financial Advisors now owns 22,105 shares of the biotechnology company’s stock valued at $198,000 after acquiring an additional 1,527 shares in the last quarter. Counterweight Ventures LLC lifted its position in shares of BioCryst Pharmaceuticals by 2.1% during the 4th quarter. Counterweight Ventures LLC now owns 95,384 shares of the biotechnology company’s stock valued at $744,000 after acquiring an additional 2,000 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in BioCryst Pharmaceuticals by 26.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 2,115 shares in the last quarter. 85.88% of the stock is owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Price Performance

The firm has a market capitalization of $2.79 billion, a price-to-earnings ratio of -6.17 and a beta of 0.55. The business’s fifty day simple moving average is $8.99 and its 200 day simple moving average is $8.35.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) EPS for the quarter, missing analysts’ consensus estimates of $0.06 by ($3.04). The firm had revenue of $156.41 million during the quarter, compared to the consensus estimate of $151.12 million. BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. The business’s quarterly revenue was up 7.5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.20 earnings per share. Equities research analysts expect that BioCryst Pharmaceuticals, Inc. will post -2.63 earnings per share for the current fiscal year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.